Stocks · News reference
Eli Lilly (NYSE:LLY) narrows FY2026 Adj EPS guidance from $35.50-$37.00 to $35.50-$35.60 vs $34.20 analyst estimate. Raises FY2026 sales outlook from $82.000 billion-$85.000 billion to $85.000 billion-$87.000 billion vs
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.
Read original at benzingaEli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.
Read original at benzingaNasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. Energy leads, gold sinks 1.3% to $4,599.
Read original at benzinga